Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study
Gynecologic Oncology Aug 17, 2017
Altman AD, et al. – Researchers inspected the effects of number of chemotherapy cycles in women with ovarian cancer that were treated with neoadjuvant chemotherapy. In this study of a homogenous cohort of patients with stage IIIC or IV high grade serous cancers who received neoadjuvant chemotherapy (NAC), ≥ 4 cycles of NAC had a worse outcome than < 3 cycles likely due to poor prognostic factors or poor response. As per the investigation, the number of consolidation cycles did not appear to make a difference in overall survival.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries